Iron Overload Clinical Trial
Official title:
MRI-based Quantitative Susceptibility Mapping of Hepatic Iron Overload
Verified date | May 2024 |
Source | University of Wisconsin, Madison |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The overall goal of this project is to develop and validate a novel technique for Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM) of the abdomen, for non-invasive assessment of liver iron deposition. In this work, study team will develop and optimize advanced data acquisition and image reconstruction methods to enable QSM of the abdomen. Further, investigators will determine the accuracy, repeatability, and reproducibility of abdominal QSM for iron quantification in patients with liver iron overload. Excessive accumulation of iron in various organs, including the liver, which affects both adult and pediatric populations, is toxic and requires treatment aimed at reducing body iron stores. Accurate assessment of liver iron concentration is critical for the detection and staging of iron overload as well as for longitudinal monitoring during treatment. In summary, this project will develop a novel MRI-based QSM technique designed for the abdomen and will validate it in pediatric and adult patients with liver iron overload. Upon successful validation, QSM will provide accurate, repeatable, and reproducible quantification of LIC based on a fundamental property of tissue.
Status | Completed |
Enrollment | 63 |
Est. completion date | April 29, 2024 |
Est. primary completion date | April 29, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 5 Years and older |
Eligibility | Inclusion Criteria: - Ages 10 years or older at University of Wisconsin - Madison - Age 5 years or older at Stanford - Known or suspected iron overload Exclusion Criteria: - Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, etc) - Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening) - Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the MRI will be allowed to participate as long as the following criteria are met: - The subject has their own prescription for the medication. - The informed consent process is conducted prior to the self-administration of this medication - They come to the research visit with a driver |
Country | Name | City | State |
---|---|---|---|
United States | University of Wisconsin | Madison | Wisconsin |
United States | School of Medicine, Stanford University | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
University of Wisconsin, Madison | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Stanford University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Establishing the accuracy of MRI-QSM of the liver using SQUID-BLS as a reference | Determine the accuracy of abdominal QSM to quantify liver iron concentration at 1.5T and 3T, in pediatric and adult patients with liver iron overload, using superconducting quantum interference device (SQUID)-based biomagnetic liver susceptometry (BLS) as the reference. | 1.5 hours | |
Primary | Establishing the repeatability of MRI-QSM of the liver | Repeatability of MRI-QSM of the liver will be established in both pediatrics and adult participants. Each participant will be scanned at both 1.5T and 3T and at UW will repeat one of the field strengths to assess repeatability. Therefore, each participant at UW will undergo 3 MRI exams and each participant at Stanford 2 MRI exams.
Repeatability will not be tested at Stanford in order to avoid exhaustion of the patients (many of whom will be children), and to ensure the completion of acquisitions at both field strengths for validation of accuracy versus SQUID-BLS. Scanning will take 1.5 hour at University of Wisconsin and I hour at Stanford |
up to 1.5 hours | |
Primary | Establishing the reproducibility of MRI-QSM of the liver | The reproducibility of abdominal MRI-based Quantitative Susceptibility Mapping (MRI-QSM) will be characterized across field strengths (1.5Tesla and 3Tesla), in both pediatric and adult participants with iron overload The repeated acquisitions at 1.5T and 3T will enable analysis of reproducibility of MRI-QSM across field strengths. At UW only, participants repeat either the 1.5T or 3T exam, with consideration given to the subject's schedule and magnet availability. Repeat tests will be performed after removing the participants from the magnet and repositioning with new localizer images. Repeatability will not be tested at Stanford in order to avoid exhaustion of the patients (many of whom will be children), and to ensure the completion of acquisitions at both field strengths for validation of accuracy versus SQUID-BLS.
Scanning will take 1.5 hour at University of Wisconsin and I hour at Stanford |
up to 1.5 hours | |
Primary | Optimizing MRI-based QSM performance by using multiple QSM reconstruction and measurement | Multiple QSM reconstructions will be applied to each acquired dataset, to evaluate the effect of each reconstruction component on the performance of QSM.
Susceptibility measurements will be made by placing a region-of-interest in each of the nine Couinaud segments of the liver. This will allow segment-by-segment analysis as well as whole-liver analysis (by averaging over the 9 segments) of the performance of QSM. The reader performing MRI analysis will be blinded to SQUID results. Scanning will take 1.5 hour at University of Wisconsin and I hour at Stanford. |
up to 1.5 hours | |
Primary | MRI-QSM data acquisition with Breath held | An optimized acquisition will obtain 3D whole liver coverage within a ~20 second breath-hold. Data will be collected at 1.5T and 3T | 1.5 hours | |
Primary | MRI-QSM data acquisition with Free Breathing | The optimized free-breathing acquisitions (using bellows, butterfly navigators, and 2D sequential acquisitions and requiring 3-5 min each) will be performed. Data will be collected at 1.5T and 3T | 1.5 hours | |
Secondary | Comparison of MRI-based QSM of the liver to serum ferritin measurements | MRI-based QSM of the liver will be compared to serum ferritin measurements to validate MRI-QSM method. MRI-QSM visit will be scheduled within +/-2 days of serum ferritin measurement visit | up to 3.5 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04423237 -
Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT
|
||
Completed |
NCT04614779 -
Long-term Clinical Study of CN128 in Thalassemia Patients
|
Phase 2 | |
Withdrawn |
NCT03800446 -
Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood
|
N/A | |
Not yet recruiting |
NCT02833493 -
Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload
|
N/A | |
Completed |
NCT02164253 -
Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients
|
Phase 2 | |
Completed |
NCT00512226 -
Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia
|
N/A | |
Completed |
NCT00901199 -
Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload
|
Phase 2 | |
Recruiting |
NCT00378469 -
Study of the Effects of Muscular Activity on Iron Metabolism
|
N/A | |
Completed |
NCT00117507 -
Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
|
Phase 4 | |
Completed |
NCT00138684 -
Cytochrome P450 2E1 and Iron Overload
|
Phase 2 | |
Completed |
NCT03990181 -
Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol Supplement
|
N/A | |
Terminated |
NCT02274233 -
Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia
|
Phase 1 | |
Active, not recruiting |
NCT01443195 -
Iron Metabolism in Small Pre Term Newborns
|
N/A | |
Completed |
NCT01546415 -
Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia
|
Phase 4 | |
Completed |
NCT01572818 -
Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients
|
N/A | |
Not yet recruiting |
NCT00980421 -
Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children
|
Phase 3 | |
Completed |
NCT01047098 -
Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation
|
N/A | |
Recruiting |
NCT05294471 -
Fully Automated High-Throughput Quantitative MRI of the Liver
|
||
Completed |
NCT03591575 -
Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children
|
Phase 4 | |
Active, not recruiting |
NCT00907283 -
Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)
|
Phase 2 |